Rigel Pharma (RIGL) Tops Q1 EPS by 2c
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $46.64 +1.72%
EPS Growth %: -34.9%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -34.9%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Rigel Pharma (NASDAQ: RIGL) reported Q1 EPS of ($0.11), $0.02 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $12.6 million versus the consensus estimate of $11.37 million.
For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- UBS Reiterates Neutral Rating on Intuit (INTU), Says Investor Day Not 'Sentiment-Changing'
- Element Solutions (ESI) PT Lowered to $47 at UBS, Buy Rating Maintained
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
